GRC 15300

Drug Profile

GRC 15300

Alternative Names: GRC 17173; GRC15300; SAR 292833

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Developer Glenmark Pharmaceuticals Ltd; Sanofi
  • Class Analgesics
  • Mechanism of Action TRPV3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Musculoskeletal pain; Neuropathic pain; Skin disorders; Urinary incontinence

Most Recent Events

  • 31 May 2013 Sanofi completes the phase II Alchemilla trial in Neuropathic pain in USA, Czech Republic, Hungary, Poland, Russia, Slovakia & Ukraine (NCT01463397)
  • 05 Mar 2012 Phase-II clinical trials in Neuropathic pain in Czech Republic (PO)
  • 05 Mar 2012 Phase-II clinical trials in Neuropathic pain in Hungary (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top